Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease

BACKGROUND: Treatment targeted to achieve reduction in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) improves outcomes in human congestive heart failure (CHF) patients. HYPOTHESIS: A pre‐specified therapeutic algorithm that increased diuretic or pimobendan usage will reduce plasma NT‐proBNP...

Descripción completa

Detalles Bibliográficos
Autores principales: Hezzell, Melanie J., Block, Chloë L., Laughlin, Danielle S., Oyama, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189340/
https://www.ncbi.nlm.nih.gov/pubmed/30216549
http://dx.doi.org/10.1111/jvim.15228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189340/
https://www.ncbi.nlm.nih.gov/pubmed/30216549
http://dx.doi.org/10.1111/jvim.15228

Ejemplares similares